Vertex Pharmaceuticals (VRTX) Return on Invested Capital (2012 - 2025)
Vertex Pharmaceuticals (VRTX) posted quarterly Return on Invested Capital of 0.19% for Q3 2025, up 18.0% year-over-year from 0.16% in Q3 2024, and up 35.01% quarter-over-quarter from 0.14% in Q2 2025.
Vertex Pharmaceuticals (VRTX) Return on Invested Capital (2012 - 2025) Analysis & Trends
Vertex Pharmaceuticals' Return on Invested Capital history runs 12 years deep, the most recent figure standing at 0.19% for Q3 2025.
- In Q3 2025, Return on Invested Capital rose 18.0% year-over-year to 0.19%; the TTM figure through Sep 2025 stood at 0.19% (up 18.0% YoY), while the FY2024 annual figure was 0.02%, down 5.0% from the prior year.
- Return on Invested Capital for Q3 2025 stood at 0.19%, up from 0.14% in the prior quarter.
- The five-year high for Return on Invested Capital was 0.19% in Q3 2025, with the low at 0.1% in Q1 2025.
- The 5-year median for Return on Invested Capital is 0.06% (2022), against an average of 0.05%.
- Peak annual rise in Return on Invested Capital reached 18 bps in 2025, while the deepest fall reached 19 bps in 2025.
- Vertex Pharmaceuticals' Return on Invested Capital stood at 0.04% in 2021, then soared by 57 bps to 0.07% in 2022, then climbed by 7 bps to 0.07% in 2023, then sank by 82 bps to 0.01% in 2024, then surged by 1349 bps to 0.19% in 2025.
- Business Quant data shows VRTX's Return on Invested Capital at 0.19% in Q3 2025, 0.14% in Q2 2025, and 0.1% in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROIC (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 0.04% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 0.00% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -0.05% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -0.35% |
| 10 | Roivant Sciences | 26.16 Bn | 26.85 Bn | 1.16 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | 0.19% |
| Jun 30, 2025 | 0.14% |
| Mar 31, 2025 | -0.10% |
| Dec 31, 2024 | 0.01% |
| Sep 30, 2024 | 0.01% |
| Jun 30, 2024 | 0.02% |
| Mar 31, 2024 | 0.08% |
| Dec 31, 2023 | 0.07% |
| Sep 30, 2023 | 0.07% |
| Jun 30, 2023 | 0.07% |
| Mar 31, 2023 | 0.07% |
| Dec 31, 2022 | 0.07% |
| Sep 30, 2022 | 0.06% |
| Jun 30, 2022 | 0.06% |
| Mar 31, 2022 | 0.05% |
| Dec 31, 2021 | 0.04% |
| Sep 30, 2021 | 0.04% |
| Jun 30, 2021 | 0.03% |
| Mar 31, 2021 | 0.04% |
| Dec 31, 2020 | 0.04% |